Regulation by Immune Response to Vaccine by Botanicals
Regulation by Immune Response to Vaccine by Botanicals
批准号:
6946042
负责人:
PHILIP O. LIVINGSTON
金额:
$29.29万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-04-01 至 2010-03-31
关键词:
T lymphocytealternative medicineantigen antibody reactionautoantigenscell mediated lymphocytolysis testcell proliferationchemical conjugatedietary supplementsdrug interactionsdrug screening /evaluationenzyme linked immunosorbent assayflow cytometryhemocyaninimmune responseimmunomodulatorslaboratory mousemedicinal plantsneoplasm /cancer vaccineoral administrationplant extracts
中文摘要
推动这个项目的假设是,今天广泛使用的一些植物可以作为
当口服时,免疫调节剂,或当皮下施用时,免疫佐剂与疫苗混合,增强或抑制针对共同施用的疫苗的免疫应答。根据我们的经验,最佳佐剂是来自南美树Quillaja saponaria Molina的树皮的QS-21和GPI-0100三萜皂苷。然而,迫切需要更有效的方法来进一步增强疫苗的免疫原性。当与globo H-KLH和GD 2-KLH结合疫苗一起给药时,将测定选定植物药的佐剂和免疫调节剂活性。
Globo H是一种在乳腺癌和大多数其他上皮癌中过表达的六碳自身抗原。GD 2是在肉瘤、神经母细胞瘤和黑色素瘤上过表达的神经节苷脂自身抗原。匙孔血蓝蛋白(KLH)是从匙孔血吸虫血液中纯化的一种有效的免疫载体蛋白。将在ELISA、FACS和细胞毒性试验中测定对globo H和KLH的抗体应答,并将在增殖和ELISPOT试验中测定对KLH的T细胞应答。将植物药与globo H-KLH疫苗混合进行试验,在目标1中仅作为佐剂,在目标2中作为免疫调节剂
口服给药,在目标3中作为佐剂与GPI-0100组合,或在目标4中与GD 2-KLH疫苗加植物作为佐剂或免疫调节剂在确定的GD 2阳性癌症的情况下给药。在任何试验中发现具有一致活性的植物药将被送回研究资源中心进行进一步纯化和表征。将再次检测所得纯化组分的佐剂和免疫调节剂活性。通过这种方式,将确定具有佐剂或免疫调节剂活性的广泛使用的植物药,并确定其最有效的成分。虽然我们的偏见是峰值反应性将发生在纯化的级分或纯化级分的组合中,但峰值反应性也可能发生在纯度较低的植物混合物中,因为可能存在我们目前不了解的问题和因素。此外,有很长的历史记录复杂佐剂制剂的效力。在我们寻找最具免疫反应性的植物药材或植物馏分时,我们将警惕这种可能性。我们还将警惕我们筛选的植物药中的负免疫调节活性,因为这将表明植物药不应与疫苗一起服用,或者在新的免疫应答很重要的其他时候服用。因此,我们有两个议程贯穿每个具体目标:1)确定广泛使用的植物对免疫系统识别和对抗免疫原的能力的积极或消极影响,以及2)定义这些植物中最有效的部分或成分,用作佐剂或免疫调节剂与癌症疫苗。
英文摘要
The hypothesis driving this project is that some of the botanicals in wide use today can act as
immunomodulators when taken orally, or immunological adjuvants when administered subcutaneously mixed with vaccines, augmenting or dampening the immune response against the co-administered vaccine. The optimal adjuvants in our experience are the QS-21 and GPI-0100 triterpenoid saponins derived from the bark of the South American tree Quillaja saponaria Molina. There is, however, a pressing need for more potent approaches to further augmenting vaccine immunogenicity. Adjuvant and immunomodulator activity will be determined for selected botanicals when administered with globo H-KLH and GD2-KLH conjugate vaccines.
Globo H is a hexaccharide auto-antigen overexpressed in breast cancers and most other epithelial cancers. GD2 is a ganglioside auto-antigen overexpressed on sarcomas, neuroblastomas, and melanomas. Keyhole limpet hemocyanin (KLH) is a potent immunological carrier protein purified from the blood of the keyhole limpet. The antibody response to globo H and KLH will be determined in ELISA, FACS, and cytotoxicity assays, and the T-cell response to KLH will be measured in proliferation and ELISPOT assays. The botanicals will be tested mixed with the globo H-KLH vaccine in Aim 1 as adjuvant alone, in Aim 2 as immunomodulator
administered orally, in Aim 3 as adjuvant in combination with GPI-0100, or in Aim 4 with a GD2-KLH vaccine plus botanical as adjuvant or immunomodulator in the setting of established, GD2 positive cancer. Botanicals found to be consistently active in any assay will be referred back to the Research Resource Core for further purification and characterization. Adjuvant and immunomodulator activity of the resulting purified components will be tested again. In this way, widely used botanicals with adjuvant or immunomodulator activity will be identified and their most active components defined. While our bias is that peak reactivity will occur with purified fractions or combinations of purified fractions, it is also possible that peak reactivity will occur with less pure botanical mixtures since there may be issues and factors operating that we do not currently understand. Also, there is a long history documenting the potency of complex adjuvant formulations. In our search for the most immunoreactive botanicals or botanical fractions, we will be alert to this possibility. We will also be alert for negative immunomodulatory activity in the botanicals we screen, as this will suggest botanicals that should not be taken with vaccines or at other times when new immune responses are important. We have, therefore, 2 agendas that run through each of the specific aims: 1) to determine the positive or negative impact of widely used botanicals on the immune system's ability to recognize and react against immunogens, and 2) to define the most active fractions or components of these botanicals for use as adjuvants or as immunomodulators with vaccines against cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil
-
批准号:8779665
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Human Monoclonal Antibodies from Immunized Patient Lymphocytes
-
批准号:7405003
-
项目类别:
-
资助金额:$19.78万
-
财政年份:2008
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Immune Monitoring
-
批准号:7728800
-
项目类别:
-
资助金额:$12.5万
-
财政年份:2008
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien
-
批准号:7801424
-
项目类别:
-
资助金额:$53.57万
-
财政年份:2008
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Pilot trial with a tetravalent conjugate vaccine against small cell lung cancer
-
批准号:7325719
-
项目类别:
-
资助金额:$20.18万
-
财政年份:2007
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Development of Antibody and T-Cell Inducing Vaccines
-
批准号:6952121
-
项目类别:
-
资助金额:$28.35万
-
财政年份:2005
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
GLYCOLIPID AND PROTEIN VACCINES AGAINST CANCER
-
批准号:6563801
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2002
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
GLYCOLIPID AND PROTEIN VACCINES AGAINST CANCER
-
批准号:6423086
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2001
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH ACTIVE AND PASSIVE IMMUNOTHERAPY AGAINST OVARIAN CANCER
-
批准号:6334957
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2000
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
GLYCOLIPID AND PROTEIN VACCINES AGAINST CANCER
-
批准号:6300242
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2000
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
DEVELOPMENT OF CANCER VACCINES
-
批准号:6102118
-
项目类别:
-
资助金额:$28.01万
-
财政年份:1999
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH ACTIVE AND PASSIVE IMMUNOTHERAPY AGAINST OVARIAN CANCER
-
批准号:6203171
-
项目类别:
-
资助金额:$26.78万
-
财政年份:1999
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
DEVELOPMENT OF CANCER VACCINES
-
批准号:6269152
-
项目类别:
-
资助金额:$26.93万
-
财政年份:1998
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH ACTIVE AND PASSIVE IMMUNOTHERAPY AGAINST OVARIAN CANCER
-
批准号:6102612
-
项目类别:
-
资助金额:$26.78万
-
财政年份:1998
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
DEVELOPMENT OF CANCER VACCINES
-
批准号:6236654
-
项目类别:
-
资助金额:$25.13万
-
财政年份:1997
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CONSTRUCTION OF VACCINES AGAINST BREAST CANCER
-
批准号:2102174
-
项目类别:
-
资助金额:$19.46万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH A POLYVALENT BREAST CANCER VACCINE
-
批准号:2008350
-
项目类别:
-
资助金额:$28.97万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CONSTRUCTION OF VACCINES AGAINST BREAST CANCER
-
批准号:2102176
-
项目类别:
-
资助金额:$20.48万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH A POLYVALENT BREAST CANCER VACCINE
-
批准号:2882392
-
项目类别:
-
资助金额:$30.59万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CONSTRUCTION OF VACCINES AGAINST BREAST CANCER
-
批准号:2102175
-
项目类别:
-
资助金额:$19.92万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
海外基金